Compare CPHC & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPHC | TIL |
|---|---|---|
| Founded | 1994 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.3M | 74.7M |
| IPO Year | 2016 | 2021 |
| Metric | CPHC | TIL |
|---|---|---|
| Price | $15.62 | $8.81 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $125.00 |
| AVG Volume (30 Days) | 1.4K | ★ 57.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.81% | N/A |
| EPS Growth | N/A | ★ 52.54 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $59,227,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.14 | N/A |
| 52 Week Low | $14.49 | $5.67 |
| 52 Week High | $21.61 | $42.75 |
| Indicator | CPHC | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 51.19 | 53.12 |
| Support Level | $15.06 | $6.85 |
| Resistance Level | $16.02 | $9.81 |
| Average True Range (ATR) | 0.29 | 0.66 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 64.02 | 50.58 |
Canterbury Park Holding Corp is in the business of pari-mutuel wagering on horse races and unbanked card games at its canterbury park racetrack and card casino facility in Minnesota. The company has four operating segments. The horse racing segment represents pari-mutuel wagering operations on simulcast and lives horse races; the Casino segment represents unbanked card operations; the food and beverage segment includes concessions, catering, and events services provided at the Racetrack; and the development segment represents its real estate development operations. The firm generates a majority of its revenue from the Casino segment.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.